Definition of treatment goals for moderate to severe psoriasis: a European consensus
about
Lifestyle changes for treating psoriasisInterventions for guttate psoriasisPromising new treatments for psoriasisApremilast in the therapy of moderate-to-severe chronic plaque psoriasisBurden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian PerspectiveThe German National Program on Psoriasis Health Care 2005-2015: results and experiencesProfile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisManaging Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care PractitionersNew and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsManagement of psoriasis patients with hepatitis B or hepatitis C virus infectionWhy quality of life measurement is important in dermatology clinical practice: An expert-based opinion statement by the EADV Task Force on Quality of Life.Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort.Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study).Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP).Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment.Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.Development of a set of process and structure indicators for palliative care: the Europall projectA Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris.Use of biologic agents in combination with other therapies for the treatment of psoriasisTopical herbal medicine combined with pharmacotherapy for psoriasis: a systematic review and meta-analysis.[Nail psoriasis--an ignored disorder. Pathogenesis, diagnosis and therapy].Association between moderate to severe psoriasis and periodontitis in a Scandinavian population.Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece.Add-on effect of chinese herbal medicine bath to phototherapy for psoriasis vulgaris: a systematic review.Oral granulated Chinese herbal medicine (YXBCM01) plus topical calcipotriol for psoriasis vulgaris: study protocol for a double-blind, randomized placebo controlled trial.The index 'Treatment Duration Control' for enabling randomized controlled trials with variation in duration of treatment of chronic pain patientsComparison of Treatment Goals for Moderate-to-Severe Psoriasis between Korean Dermatologists and the European Consensus Report.Non-alcoholic fatty liver disease and psoriasis: So far, so near.Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trialsIt is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis.Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 yearsOral Chinese herbal medicine versus placebo for psoriasis vulgaris: A systematic review.Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study.Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.An analysis of dermatological quality-of-life scores in relation to psychiatric morbidity in psoriasis.An evolution in switching therapy for psoriasis patients who fail to meet treatment goals.
P2860
Q24188109-6DD93D75-5446-4A92-86B3-CAB8ADDD6AB8Q24188296-127183DF-D64A-4DDD-AE28-9C716C4BBA4EQ24598008-F205292A-D83E-4DFA-9BE2-A9945A387846Q26745789-E513DF19-A08A-419A-82DF-F3E17EE4BA80Q26747639-018DA5E3-E4C0-418E-8463-7406BAF2B072Q26751448-F0F7DC30-ECF6-4D77-975C-A6F74E29B83BQ26765028-A633C36A-744A-4AA2-9E49-FABDF8E44373Q26771785-90AE0B2E-E4E0-4117-BE80-7CF7EEAED105Q26800937-DCE0FC84-3ACF-41E9-A845-43555BAA330AQ28078157-4E437F0A-586C-4F6C-A379-E88AE40C8EC3Q30244189-441EAF9F-07EE-4336-B3E4-D38A8862650DQ30769599-2D304302-1042-4798-82BB-202E624C21FEQ31034328-562B4DF0-9073-4BC1-B370-D174ACF14E06Q33651502-DBE94A68-36C0-4974-BD19-8E25A3E91F7BQ34071609-86022F3C-5B18-4428-9805-D69D59D7B7AAQ34166896-5460C2CF-5E0D-4646-BA88-69CC38774E6FQ34190076-4D74D077-3726-4E17-9F68-BF3D982FF2DAQ34196035-A728FD8F-0A08-4304-8F67-FF0746682F4CQ34393068-8B059B77-7F05-4EA2-9F99-C4DCFEB24B29Q34465992-C4540C88-D3D5-4203-AC05-05EB5AADE243Q34487520-ECE51C28-6A74-4814-9BFB-AED1E7ACFF86Q34553755-CBF12DB1-905A-4499-8CF7-E06618CD3E3BQ34564903-1DC41353-5B40-4A45-9D50-A683AF6AC007Q34636311-B42E549A-5425-420B-9EC9-FCF03F4E4DDBQ34793808-EC7441DC-C386-4A8C-9076-5673E6E127D2Q34944668-069FA1D5-B5F0-4108-8C19-F591752B738EQ34975485-ECA7C08C-8C58-4132-A6C3-AB01B6A64E16Q34996214-B0A8B546-6DC9-428D-BD43-3DB5F9633F9CQ35013672-B80A8C52-130B-44EE-88DD-D0B761A14B24Q35226809-50861CE2-0670-4AB2-A493-408C0A192B4EQ35237307-7322B66A-1030-465A-BC28-36EF7AADA514Q35643453-2B065253-66C6-43C1-B4B2-5EA87339C854Q35905924-588EC9A6-CF0D-47EB-8D7C-53E171436CE2Q36048427-505886D6-9BD2-4237-9338-492A0F4CE488Q36065742-EE0BA8DF-8310-4D28-9BEC-08AC3474BAA7Q36628064-3CF1EB71-7AD8-46E6-9C6C-45710CFEE988Q36631474-0927224E-AA02-45A7-B015-C3C7F814DFD3Q36691601-BBCF1677-57E4-4B9E-8412-8DE214EF44B8Q36950400-9BE5B537-F6EC-4454-8B17-11B1790F83A2Q37295966-30F4E38D-E313-4759-AFC3-99A07307D34A
P2860
Definition of treatment goals for moderate to severe psoriasis: a European consensus
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@ast
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@en
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@nl
type
label
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@ast
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@en
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@nl
prefLabel
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@ast
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@en
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@nl
P2093
P2860
P50
P3181
P1476
Definition of treatment goals for moderate to severe psoriasis: a European consensus
@en
P2093
B Volc-Platzer
C Antoniou
K Kragballe
P2860
P2888
P3181
P356
10.1007/S00403-010-1080-1
P407
P577
2010-09-21T00:00:00Z
P5875
P6179
1033127072